This hospital-based, interventional, comparative and prospective follow-up, single-blind randomized trial will be conducted in patients on antipsychotic use. The aim of this study will be to compare the efficacy and safety of two drugs i.e., metformin and dapagliflozin on weight gain in patients of Bipolar II depression treated with olanzapine–fluoxetine combination.Patients with depressive symptoms visiting outpatient department and/or admitted in inpatient department of psychiatry department will be screened for bipolar disorder using mood disorder questionnaire. Those patients who score >7 on mood disorder questionnaire will be assessed further using young mania rating scale to rule out mania. Patients who score ≤ 12 on young mania rating scale will be interviewed and diagnosed bipolar-II depression as per ICD-11 criteria. Severity of bipolar-II depression will be assessed using bipolar depression rating scale score and clinical global impression – bipolar illness score. Quality of life will be assessed using world health organization quality of life brief version score. These patients will then be screened according to the inclusion and exclusion criteria after recording the relevant physical parameters and lab investigations. Patients put on olanzapine-fluoxetine combination with or without adjunct medication for sleep/anxiety e.g. benzodiazepines, propranolol etc. and developing olanzapine-fluoxetine combination induced weight gain (defined as ≥ 5% weight gain within one month of initiating olanzapine-fluoxetine combination) will be considered eligible. To establish causality, Naranjo’s causality scale will be employed. A written informed consent will be taken. Eligible participants will undergo detailed  assessment  as per predesigned psychiatric proforma which will assess the socio-demographic profile, illness related details including seasonality, physical parameters including weight, body mass index, waist circumference, blood pressure and lab investigations including fasting lipid profile, fasting blood sugar, haemoglobin A1c etc. Patients will then be randomly allocated into two groups of 62 patients each. Group A will be given olanzapine-fluoxetine combination plus tablet metformin 1000 mg daily for a period for 24 weeks. Group B will be given olanzapine-fluoxetine combination plus tablet dapagliflozin 10 mg daily for a period for 24 weeks. Enrolled patients of two groups will be followed-up and the observations will be recorded at 0 week, 4 weeks, 12 weeks and 24 weeks after initiating weight lowering drugs. Data will be kept strictly confidential. Changes in the parameters of primary and secondary outcomes at the time of visit will be noted and will be subjected to appropriate statistical analysis.